Managed Healthcare Executive

FDA approves once daily pill Icotyde for plaque psoriasis

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.

FDA approval of ICOTYDEâ„¢ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDEâ„¢ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...

Johnson & Johnson: FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...